PIM kinases: An overview in tumors and recent advances in pancreatic cancer

Future Oncology

Volumn 10, Issue 5, 2014, Pages 865-876

  Xu, Jianwei ^a   Zhang, Taiping ^a   Wang, Tianxiao ^a   You, Lei ^a   Zhao, Yupei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

inhibitors; pancreatic cancer; PIM kinases; prognosis; tumorigenesis

Indexed keywords

ABC TRANSPORTER; CYTARABINE; DOCETAXEL; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; SUNITINIB; UNCLASSIFIED DRUG; VORINOSTAT; ONCOPROTEIN; PIM1 PROTEIN, HUMAN; PIM2 PROTEIN, HUMAN; PIM3 PROTEIN, HUMAN;

APOPTOSIS; AUTOPHAGY; CANCER PROGNOSIS; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL METABOLISM; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; STEM CELL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER STAGING; GENETICS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PATHOLOGY;

APOPTOSIS; CELL PROLIFERATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84899785377     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.229     Document Type: Review

References (104)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA. Cancer J. Clin. 63(1), 11-30 (2013).
2. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J. Surg. Oncol. 107(1), 15-22 (2013).
3. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817-1825 (2011).
4. Ueno H, Ioka T, Ikeda M et al. Randomized Phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J. Clin. Oncol. 31(13), 1640-1648 (2013).
5. Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer. World J. Gastroenterol. 18(35), 4944-4958 (2012).
6. Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 18(6), 653-664 (2012).
7. Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev. Hematol. 5(1), 81-96 (2012).
8. Wang Z, Bhattacharya N, Weaver M et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J. Vet. Sci. 2(3), 167-179 (2001).
9. Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 102(8), 1437-1442 (2011).
10. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17(15), 1841-1854 (2003).
11. Cuypers HT, Selten G, Quint W et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37(1), 141-150 (1984).
12. Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem. Pharmacol. 85(5), 629-643 (2012).
13. Merkel AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin. Investig. Drugs 21(4), 425-436 (2012).
14. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 8(3), 743-748 (1989).
15. Feldman JD, Vician L, Crispino M, Tocco G, Baudry M, Herschman HR. Seizure activity induces PIM-1 expression in brain. J. Neurosci. Res. 53(4), 502-509 (1998).
16. Konietzko U, Kauselmann G, Scafidi J et al. Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBO J. 18(12), 3359-3369 (1999).
17. Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol. 37(4), 726-730 (2005).
18. Brault L, Menter T, Obermann EC et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br. J. Cancer 107(3), 491-500 (2012).
19. Ayala GE, Dai H, Ittmann M et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 64(17), 6082-6090 (2004).
20. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol. Cell. Biol. 23(11), 3897-3908 (2003).
21. Fujii C, Nakamoto Y, Lu P et al. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int. J. Cancer 114(2), 209-218 (2005).
22. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 66(13), 6741-6747 (2006).
23. Zheng HC, Tsuneyama K, Takahashi H et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J. Cancer Res. Clin. Oncol. 134(4), 481-488 (2008).
24. Mizuki M, Schwable J, Steur C et al. Suppression of myeloid transcription factors and induction of STAT response genesby AML-specific Flt3 mutations. Blood 101(8), 3164-3173 (2003).
25. Cohen AM, Grinblat B, Bessler H et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia andnon-Hodgkin lymphoma. Leuk. Lymphoma 45(5), 951-955 (2004).
26. Sharma P, Saraya A, Gupta P, Sharma R. Decreased levels of circulating and tissue miR-107 in human esophageal cancer. Biomarkers 18(4), 322-330 (2013).
27. Pasqualucci L, Neumeister P, Goossens T et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412(6844), 341-346 (2001).
28. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001).
29. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl Acad. Sci. USA 86(22), 8857-8861 (1989).
30. Guo S, Mao X, Chen J et al. Overexpression of Pim-1 in bladder cancer. J. Exp. Clin. Cancer Res. 29, 161 (2010).
31. Buchholz M, Braun M, Heidenblut A et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24(44), 6626-6636 (2005).
32. Reiser-Erkan C, Erkan M, Pan Z et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 7(9), 1352-1359 (2008).
33. Peltola K, Hollmen M, Maula SM et al. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 11(7), 629-636 (2009).
34. Malinen M, Jaaskelainen T, Pelkonen M et al. Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Mol. Cell. Endocrinol. 365(2), 270-276 (2013).
35. Miura O, Miura Y, Nakamura N et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 84(12), 4135-4141 (1994).
36. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via theNF-kappa B pathway. J. Immunol. 168(2), 744-754 (2002).
37. Chen J, Kobayashi M, Darmanin S et al. Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am. J. Pathol. 175(1), 400-411 (2009).
38. Shen J, Xia W, Khotskaya YB et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylationof AGO2. Nature 497(7449), 383-387 (2013).
39. Bednarski JJ, Nickless A, Bhattacharya D, Amin RH, Schlissel MS, Sleckman BP. RAG-induced DNA double-strand breaks signal through Pim2 to promote pre-B cell survival and limit proliferation. J. Exp. Med. 209(1), 11-17 (2012).
40. Xu D, Allsop SA, Witherspoon SM et al. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis 32(4), 488-495 (2011).
41. Selmi T, Martello A, Vignudelli T et al. ZFP36 expression impairs glioblastoma cell lines viability and invasiveness by targeting multiple signal transduction pathways. Cell Cycle 11(10), 1977-1987 (2012).
42. Li YY, Wu Y, Tsuneyama K, Baba T, Mukaida N. Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells. Cancer Sci. 100(3), 396-404 (2009).
43. Kim KT, Carroll AP, Mashkani B, Cairns MJ, Small D, Scott RJ. MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1cells and interacts with Pim-1. PLoS ONE 7(9), e44546 (2012).
44. Thomas M, Lange-Grunweller K, Weirauch U et al. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31(7), 918-928 (2012).
45. Chen J, Yin H, Jiang Y et al. Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation. Arterioscler. Thromb. Vasc. Biol. 31(2), 368-375 (2011).
46. Eiring AM, Harb JG, Neviani P et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140(5), 652-665 (2010).
47. Lang MF, Yang S, Zhao C et al. Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS ONE 7(4), e36248 (2012).
48. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 283(30), 20635-20644 (2008).
49. Wozniak MB, Villuendas R, Bischoff JR et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 95(4), 613-621 (2010).
50. Aksoy I, Sakabedoyan C, Bourillot PY et al. Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3. Stem Cells 25(12), 2996-3004 (2007).
51. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 274(26), 18659-18666 (1999).
52. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int. J. Biochem. Cell Biol. 38(3), 430-443 (2006).
53. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim. Biophys. Acta 1593(1), 45-55 (2002).
54. Leverson JD, Koskinen PJ, Orrico FC et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol. Cell 2(4), 417-425 (1998).
55. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulatingp27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 68(13), 5076-5085 (2008).
56. Levy D, Davidovich A, Zirkin S et al. Activation of cell cycle arrest and apoptosis by the proto-oncogene Pim-2. PLoS ONE 7(4), e34736 (2012).
57. Wang Z, Zhang Y, Gu JJ, Davitt C, Reeves R, Magnuson NS. Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells. Int. J. Biochem. Cell Biol. 42(6), 1030-1038 (2010).
58. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 571(1-3), 43-49 (2004).
59. Xu D, Cobb MG, Gavilano L et al. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol. Ther. 14(6), 492-501 (2013).
60. Bohensky J, Shapiro IM, Leshinsky S, Watanabe H, Srinivas V. PIM-2 is an independent regulator of chondrocyte survival and autophagy in the epiphyseal growth plate. J. Cell. Physiol. 213(1), 246-251 (2007).
61. Gu JJ, Wang Z, Reeves R, Magnuson NS. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 28(48), 4261-4271 (2009).
62. Zhang F, Beharry ZM, Harris TE et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1cells. Cancer Biol. Ther. 8(9), 846-853 (2009).
63. Hammerman PS, Fox CJ, Cinalli RM et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res. 64(22), 8341-8348 (2004).
64. Hogan C, Hutchison C, Marcar L et al. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway incultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J. Biol. Chem. 283(26), 18012-18023 (2008).
65. Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol. Cancer Res. 8(8), 1126-1141 (2010).
66. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 36(Suppl. 3), S3-3S17 (2009).
67. Laplante M, Sabatini DM. mTOR signaling at a glance. J. Cell. Sci. 122(Pt 20), 3589-3594 (2009).
68. Beharry Z, Mahajan S, Zemskova M et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc. Natl Acad. Sci. USA 108(2), 528-533 (2011).
69. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11(9), 709-730 (2012).
70. Pyo JO, Nah J, Jung YK. Molecules and their functions in autophagy. Exp. Mol. Med. 44(2), 73-80 (2012).
71. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12(Suppl. 2) 1509-1518 (2005).
72. Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103(12), 4536-4544 (2004).
73. Tjwa M, Dimmeler S. A nucleolar weapon in our fight for regenerating adult hearts: nucleostemin and cardiac stem cells. Circ. Res. 103(1), 4-6 (2008).
74. Fischer KM, Cottage CT, Wu W et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 120(21), 2077-2087 (2009).
75. An N, Kraft AS, Kang Y. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice: Pim kinase regulates hematopoiesis. J. Hematol. Oncol. 6(1), 12 (2013).
76. Agrawal S, Koschmieder S, Baumer N et al. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. Leukemia 22(1), 78-86 (2008).
77. Tsuzuki S, Seto M. TEL(ETV6)-AML1(RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice. Stem Cells 31(2), 236-247 (2012).
78. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20(11), 1915-1924 (2006).
79. Lapidot T, Dar A, Kollet O. How do stem cells find their way home. Blood 106(6), 1901-1910 (2005).
80. Grundler R, Brault L, Gasser C et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J. Exp. Med. 206(9), 1957-1970 (2009).
81. Isaac M, Siu A, Jongstra J. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resist. Updat. 14(4-5), 203-211 (2011).
82. Xie Y, Xu K, Linn DE et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J. Biol. Chem. 283(6), 3349-3356 (2008).
83. Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol. Pharmacol. 78(2), 310-318 (2010).
84. Natarajan K, Bhullar J, Shukla S et al. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem. Pharmacol. 85(4), 514-524 (2012).
85. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemiacells. Blood 114(19), 4150-4157 (2009).
86. Mumenthaler SM, Ng PY, Hodge A et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther. 8(10), 2882-2893 (2009).
87. Toffoli S, Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J. 275(12), 2991-3002 (2008).
88. Chen J, Kobayashi M, Darmanin S et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28(28), 2581-2592 (2009).
89. Mikkers H, Nawijn M, Allen J et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell. Biol. 24(13), 6104-6115 (2004).
90. Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opin. Ther. Targets 11(5), 673-694 (2007).
91. Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y et al. The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis 33(8), 1479-1486 (2012).
92. Mahalingam D, Espitia CM, Medina EC et al. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br. J. Cancer 105(10), 1563-1573 (2011).
93. Kelly KR, Espitia CM, Taverna P et al. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br. J. Haematol. 156(1), 129-132 (2012).
94. Pierre F, Chua PC, O'Brien SE et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol. Cell. Biochem. 356(1-2), 37-43 (2011).
95. Pierre F, Stefan E, Nedellec AS et al. 7-(4H-1,2,4-triazol-3-yl)benzo[c] [2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg. Med. Chem. Lett. 21(22), 6687-6692 (2011).
96. Barnett A, Ding S, Murray C et al. Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: human tumor xenograft efficacy and in vitro mode of action. EJC Suppl. 8(7), 45-46 (2010).
97. Siu A, Virtanen C, Jongstra J. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget 2(12), 1134-1144 (2011).
98. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27(35), 4809-4819 (2008).
99. Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas 41(5), 773-781 (2012).
100. Wang C, Li HY, Liu B, Huang S, Wu L, Li YY. Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor. J. Surg. Res. 185(2), 595-604 (2013).
101. Chang M, Kanwar N, Feng E et al. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol. Cancer Ther. 9(9), 2478-2487 (2010).
102. Wang YY, Taniguchi T, Baba T, Li YY, Ishibashi H, Mukaida N. Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity. Cancer Sci. 103(1), 107-115 (2012).
103. Li YY, Wang YY, Taniguchi T et al. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability. Int. J. Cancer 127(2), 474-484 (2010).
104. Wang Z, Li XM, Shang K et al. T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug. Oncol. Rep. 29(3), 1245-1251 (2013).